Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial
We aimed to compare the efficacy and safety of nab-paclitaxel plus gemcitabine with nab-Paclitaxel plus gemcitabine. Adults (aged 18–75 years) with an Eastern Cooperative Oncology Group were randomly assigned. Median overall survival was 18.5 months (95% CI 14.4–21.5) in the nab.-paclitaxel group and 20.7 months in the fOLFIRinoX group.
